Multiple Myeloma
Conference Coverage
Will quad therapy become the new standard in myeloma?
NEW YORK – Phase 2 studies have shown high response rates for four-drug combinations targeting multiple myeloma.
Conference Coverage
STORM trial shows response in penta-refractory myeloma
Selinexor and low-dose dexamethasone produced a “clinically meaningful benefit” in the phase 2 trial.
Conference Coverage
Occurrence of Skeletal-Related Events in Multiple Myeloma and Prostate Cancer Patients Receiving Standard Versus Extended-Interval Zoledronic Acid
News
Fracture risk linked to mortality in women with myeloma
Researchers identified osteoporosis as an important prognostic factor in postmenopausal women.
News
Treatment simulation could help personalize myeloma therapy
A simulation helped identify whether patients would benefit most from treatment with bortezomib or lenalidomide.
News
Myeloma frailty index predicts survival based on biological age
The index, developed after a retrospective analysis of 2.7 million records of noncancer patients and validated with records for 305 multiple...
News
Promising phase 3 results for ixazomib in multiple myeloma
The drug met the primary endpoint in a phase 3 study of maintenance therapy after stem cell transplant.
Conference Coverage
Ruxolitinib overcame lenalidomide resistance in myeloma
The clinical trial is the first to demonstrate the activity of a JAK inhibitor in the treatment of myeloma patients.
News
CAR T therapy to enter early testing in multiple myeloma
The phase 1b/2 trial will begin enrollment in the second half of 2018.
News
More evidence links increased BMI to higher multiple myeloma risk
MM risk rose almost 30% for every 5 kg/m2 increase in young adult BMI.